Literature DB >> 3260833

Response of human coronary arteries to aggregating platelets: importance of endothelium-derived relaxing factor and prostanoids.

U Förstermann1, A Mügge, S M Bode, J C Frölich.   

Abstract

Epicardial human coronary arteries (HCA) were obtained during heart transplantation. Strip preparations were mounted for isometric tension recording. Tension was induced with prostaglandin F2 alpha (0.3-3 microM). Aggregating human platelets (10(7)/ml and 10(8)/ml) caused marked relaxation if the endothelium of the HCA was intact, but produced modest additional constriction if the endothelium was removed. The endothelium-dependent relaxations to platelets were slightly enhanced in the presence of methysergide (1 microM) or after treatment of the platelets with the thromboxane synthase inhibitor dazmegrel (1 mM, 30 minutes). Relaxations to platelets were markedly inhibited or abolished in the presence of apyrase (1 unit/ml), after selective pretreatment of HCA with gossypol or methylene blue (both 30 microM, 30 minutes), or after addition of hemoglobin (20 microM) to the organ bath. Pretreatment of HCA (not the platelets) with aspirin (30 microM, 30 minutes) had no significant effect on platelet-induced relaxations. Adenosine 5'-diphosphate (0.1-100 microM) induced marked relaxations in endothelium-intact and much smaller relaxations in endothelium-denuded HCA. A low concentration (10 nM) of serotonin (5-HT) produced modest endothelium-dependent relaxations, higher concentrations (0.1-1 microM) led to increases in tension (also in the presence of endothelium). The thromboxane A2 mimetic U44069 (1-100 nM) was the most potent constrictor of HCA irrespective of the presence or absence of endothelium. After inhibition of thromboxane synthase, platelets produced large amounts of prostaglandins E2 and F2 alpha. Both prostaglandins constricted HCA, which can explain the limited effects of dazmegrel.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260833     DOI: 10.1161/01.res.63.2.306

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  9 in total

1.  Systemic low-dose aspirin and clopidogrel independently attenuate reflex cutaneous vasodilation in middle-aged humans.

Authors:  Lacy A Holowatz; John D Jennings; James A Lang; W Larry Kenney
Journal:  J Appl Physiol (1985)       Date:  2010-04-01

2.  Effect of protein kinase C and phospholipase A2 inhibitors on the impaired ability of human diabetic platelets to cause vasodilation.

Authors:  H J Oskarsson; T G Hofmeyer; L Coppey; M A Yorek
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 3.  Endogenous and exogenous nitrates and their role in myocardial ischaemia.

Authors:  T F Lüscher
Journal:  Br J Clin Pharmacol       Date:  1992       Impact factor: 4.335

4.  Ketorolac alters blood flow during normothermia but not during hyperthermia in middle-aged human skin.

Authors:  Lacy A Holowatz; John D Jennings; James A Lang; W Larry Kenney
Journal:  J Appl Physiol (1985)       Date:  2009-08-06

Review 5.  Endothelium-derived vasoactive factors and regulation of vascular tone in human blood vessels.

Authors:  T F Lüscher
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 6.  Peripheral mechanisms of thermoregulatory control of skin blood flow in aged humans.

Authors:  Lacy A Holowatz; W Larry Kenney
Journal:  J Appl Physiol (1985)       Date:  2010-04-22

Review 7.  Endothelial nitric oxide (NO) and its pathophysiologic regulation.

Authors:  Anuran Chatterjee; Stephen M Black; John D Catravas
Journal:  Vascul Pharmacol       Date:  2008-07-20       Impact factor: 5.773

8.  Chronic low-dose aspirin therapy attenuates reflex cutaneous vasodilation in middle-aged humans.

Authors:  Lacy A Holowatz; W Larry Kenney
Journal:  J Appl Physiol (1985)       Date:  2008-11-26

9.  Effects of Low-Dose Aspirin Therapy on Thermoregulation in Firefighters.

Authors:  Serina J McEntire; Steven E Reis; Oscar E Suman; David Hostler
Journal:  Saf Health Work       Date:  2015-06-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.